Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus DOLENE.
DALGAN vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic